The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

Fasinumab is from a class of drugs targeting nerve growth factor (NGF), which plays a central role in the regulation of pain signalling. The FDA had trials of NGF drugs on hold twice because of ...